Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 6,938,667 | 7,556,065 | 7,197,314 | 7,727,912 | 7,313,235 |
| Cost of Goods | 2,548,760 | 2,580,471 | 2,370,716 | 2,344,132 | 2,366,329 |
| Gross Profit | 4,389,908 | 4,975,594 | 4,826,598 | 5,383,779 | 4,946,906 |
| Operating Expenses | 4,517,065 | 4,262,650 | 5,167,774 | 4,153,343 | 4,272,038 |
| Operating Income | -126,406 | 713,415 | -340,460 | 1,230,568 | 675,189 |
| Interest Expense | 223,879 | 457,837 | 400,352 | 434,898 | -124,946 |
| Other Income | -25,504 | 160,990 | 78,550 | 190,070 | -447,150 |
| Pre-tax Income | -375,789 | 416,568 | -662,262 | 985,741 | 352,985 |
| Income Tax | -329,944 | -302,573 | -331,262 | 333,077 | 105,994 |
| Net Income Continuous | -45,845 | 719,141 | -331,000 | 652,664 | 246,991 |
| Minority Interests | 165 | 245 | 407 | 80 | 17 |
| Net Income | $-46,010 | $718,896 | $-331,407 | $652,584 | $246,974 |
| EPS Basic Total Ops | -0.02 | 0.23 | -0.11 | 0.21 | 0.08 |
| EPS Basic Continuous Ops | -0.02 | 0.23 | -0.11 | 0.21 | 0.08 |
| EPS Diluted Total Ops | -0.01 | 0.23 | -0.11 | 0.21 | 0.08 |
| EPS Diluted Continuous Ops | -0.02 | 0.23 | -0.11 | 0.21 | 0.07 |
| EPS Diluted Before Non-Recurring Items | 0.00 | 0.51 | N/A | N/A | N/A |
| EBITDA(a) | $1,216,261 | $1,950,010 | $851,542 | $2,482,526 | $2,020,529 |